Phase 3 trial of CAR T-cell therapy anito-cel for RRMM opens
Kite Pharma has initiated iMMagine-3, a global Phase 3 clinical trial that’s set to test anitocabtagene autoleucel (anito-cel), an investigational CAR T-cell therapy, against…
News
First-line induction therapy with Sarclisa delays myeloma progression
Adding Sarclisa (isatuximab) to standard induction therapy for transplant-eligible people with newly diagnosed multiple myeloma extends the time patients live without their disease…
FDA adds Darzalex Faspro to combo therapy for newly diagnosed MM
The U.S. Food and Drug Administration (FDA) has approved a new quadruple regimen including Darzalex Faspro (daratumumab and hyaluronidase-fihj) as a first-line approach for adults…
Blood test may predict patients’ responses to CAR T-cell therapy
A blood test measuring numbers of lymphocytes, a type of immune cell, may predict how well people with relapsed multiple myeloma will respond to…
Blenrep combinations for myeloma now under review in EU
A committee of the European Medicines Agency (EMA) has accepted for review GSK’s marketing authorization application for Blenrep (belantamab mafodotin) to be used as…
MMRF invests $1M to advance DCT’s new CAR T-cell therapy
Through its Myeloma Investment Fund, the Multiple Myeloma Research Foundation (MMRF) has invested $1 million in novel CAR T-cell technology from Dynamic Cell Therapies…
Leukemia & Lymphoma Society to launch 32nd Scenic Shore Bike Tour
The Leukemia & Lymphoma Society (LLS) is once again running its Scenic Shore Bike Tour to raise awareness and support for people with blood…
Analyses identify proteins tied to multiple myeloma disease course
Researchers in Germany have identified proteins that could help identify multiple myeloma patients who at high risk for an aggressive disease course and worse…
Survival in hard-to-treat myeloma extended with Elrexfio treatment
Pfizer’s Elrexfio (elranatamab) extends the lives of adults with relapsed or refractory multiple myeloma (RRMM) who received at least two prior lines of therapy and whose…
First RR multiple myeloma patient treated with ABBV-383
A Phase 3 clinical trial evaluating the safety and efficacy of AbbVie’s experimental therapy ABBV-383 in adults with relapsed or refractory multiple…
Recent Posts
- Germany clears pelareorep pancreatic cancer trial continuation
- FDA grants orphan drug status to novel brain cancer treatment
- Medicaid expansion can raise demand for gynecologic cancer care
- Under-the-skin Sarclisa found as effective as approved formulation
- FDA gives LYT-200 fast track status as potential AML treatment